Orexo and ProStrakan advance date for taking over rights for Rapinyl in North America

Orexo and ProStrakan advance date for taking over rights for Rapinyl in North
America

As announced earlier, Orexo is changing partner for Rapinyl in North America to
ProStrakan. Orexo and the former partner Endo Pharmaceuticals have now set the
date for the takeover at October 31, 2008. In conjunction with the takeover,
Orexo will receive USD 0.75m from Endo in accordance with an earlier agreement.
Orexo will also receive compensation in the amount of USD 1.5m corresponding to
Endo's earlier undertaking for the ongoing Phase III studies.

In conjunction with the current contractual transfer of Rapinyl in North America
to ProStrakan Ltd, Orexo will receive USD 2m from ProStrakan.

“We are very satisfied with advancing the takeover of rights for Rapinyl in
North America,” says Torbjörn Bjerke, President and CEO of Orexo. “With our
partner ProStrakan, we will now complete the Phase III studies, which are
expected to be concluded in December. Concurrently, we will be preparing
submission of a registration application and for the marketing of Rapinyl in
North America.”


About Rapinyl/Abstral
Rapinyl (Abstral in Europe) is a fast-dissolving tablet for sublingual (under
the tongue) administration intended for the management of breakthrough cancer
pain in patients who are already receiving opioid analgesics for pain treatment.
Orexo and partner ProStrakan plan to submit a registration application for
Rapinyl in the US during 2009. In Europe, the EMEA has recommended approval of
Abstral and the product was recently approved for sale in the UK. Since August,
Abstral is also sold in Sweden. 

About breakthrough pain
Each year, approximately 1.4 million patients are diagnosed with cancer. Between
30-30% of this group suffer acute pain, of which 64% have breakthrough pain. The
American market for treatment of breakthrough pain is estimated to exceed USD
500m annually. 


For more information, please contact: 
Torbjörn Bjerke, President and CEO, Orexo AB
Tel: +46 (0)708-66 19 90
E-mail: torbjorn.bjerke@orexo.com
Claes Wenthzel, Executive Vice President and CFO, Orexo AB 
Tel: +46 (0)708-62 01 22 
E-mail: claes.wenthzel@orexo.com

Orexo AB (publ) may be required to disclose the information provided herein
pursuant to the Swedish Securities Markets Act. The information was provided for
public release on October 31, 2008 at 08:00 a.m. CET.